GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynCore Biotechnology Co Ltd (ROCO:4192) » Definitions » EV-to-EBIT

SynCore Biotechnology Co (ROCO:4192) EV-to-EBIT : -35.88 (As of May. 11, 2024)


View and export this data going back to 2014. Start your Free Trial

What is SynCore Biotechnology Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, SynCore Biotechnology Co's Enterprise Value is NT$1,341.32 Mil. SynCore Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-37.39 Mil. Therefore, SynCore Biotechnology Co's EV-to-EBIT for today is -35.88.

The historical rank and industry rank for SynCore Biotechnology Co's EV-to-EBIT or its related term are showing as below:

ROCO:4192' s EV-to-EBIT Range Over the Past 10 Years
Min: -47.92   Med: -8.46   Max: -3.5
Current: -35.88

During the past 13 years, the highest EV-to-EBIT of SynCore Biotechnology Co was -3.50. The lowest was -47.92. And the median was -8.46.

ROCO:4192's EV-to-EBIT is ranked worse than
100% of 433 companies
in the Biotechnology industry
Industry Median: 9.43 vs ROCO:4192: -35.88

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. SynCore Biotechnology Co's Enterprise Value for the quarter that ended in Dec. 2023 was NT$1,081.09 Mil. SynCore Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-37.39 Mil. SynCore Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3.46%.


SynCore Biotechnology Co EV-to-EBIT Historical Data

The historical data trend for SynCore Biotechnology Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynCore Biotechnology Co EV-to-EBIT Chart

SynCore Biotechnology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.39 -11.78 -7.05 -14.59 -28.92

SynCore Biotechnology Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.59 -12.48 -11.73 -7.70 -28.92

Competitive Comparison of SynCore Biotechnology Co's EV-to-EBIT

For the Biotechnology subindustry, SynCore Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SynCore Biotechnology Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynCore Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SynCore Biotechnology Co's EV-to-EBIT falls into.



SynCore Biotechnology Co EV-to-EBIT Calculation

SynCore Biotechnology Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1341.315/-37.388
=-35.88

SynCore Biotechnology Co's current Enterprise Value is NT$1,341.32 Mil.
SynCore Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-37.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SynCore Biotechnology Co  (ROCO:4192) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

SynCore Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-37.388/1081.094
=-3.46 %

SynCore Biotechnology Co's Enterprise Value for the quarter that ended in Dec. 2023 was NT$1,081.09 Mil.
SynCore Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-37.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SynCore Biotechnology Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of SynCore Biotechnology Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


SynCore Biotechnology Co (ROCO:4192) Business Description

Traded in Other Exchanges
N/A
Address
No.84 Zhongshan Road, Zhongshan Village, Dongshan Township, Yilan, TWN, 269
SynCore Biotechnology Co Ltd is a biopharmaceutical company. Its pipeline products concentrate on the ophthalmology, oncology, and dermatology fields. The pipeline products of the company include SB01 and 02, SB03, SB04, and SB05. It is engaged in drug development and sale, food advisory, medicine inspection, biotechnology service and intellectual property. It operates in a single industry, the new drug development.

SynCore Biotechnology Co (ROCO:4192) Headlines

No Headlines